Cargando…

Immune phenotypes predict survival in patients with glioblastoma multiforme

BACKGROUND: Glioblastoma multiforme (GBM), a common primary malignant brain tumor, rarely disseminates beyond the central nervous system and has a very bad prognosis. The current study aimed at the analysis of immunological control in individual patients with GBM. METHODS: Immune phenotypes and plas...

Descripción completa

Detalles Bibliográficos
Autores principales: Mostafa, Haouraa, Pala, Andrej, Högel, Josef, Hlavac, Michal, Dietrich, Elvira, Westhoff, M. Andrew, Nonnenmacher, Lisa, Burster, Timo, Georgieff, Michael, Wirtz, C. Rainer, Schneider, E. Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009501/
https://www.ncbi.nlm.nih.gov/pubmed/27585656
http://dx.doi.org/10.1186/s13045-016-0272-3
_version_ 1782451524616585216
author Mostafa, Haouraa
Pala, Andrej
Högel, Josef
Hlavac, Michal
Dietrich, Elvira
Westhoff, M. Andrew
Nonnenmacher, Lisa
Burster, Timo
Georgieff, Michael
Wirtz, C. Rainer
Schneider, E. Marion
author_facet Mostafa, Haouraa
Pala, Andrej
Högel, Josef
Hlavac, Michal
Dietrich, Elvira
Westhoff, M. Andrew
Nonnenmacher, Lisa
Burster, Timo
Georgieff, Michael
Wirtz, C. Rainer
Schneider, E. Marion
author_sort Mostafa, Haouraa
collection PubMed
description BACKGROUND: Glioblastoma multiforme (GBM), a common primary malignant brain tumor, rarely disseminates beyond the central nervous system and has a very bad prognosis. The current study aimed at the analysis of immunological control in individual patients with GBM. METHODS: Immune phenotypes and plasma biomarkers of GBM patients were determined at the time of diagnosis using flow cytometry and ELISA, respectively. RESULTS: Using descriptive statistics, we found that immune anomalies were distinct in individual patients. Defined marker profiles proved highly relevant for survival. A remarkable relation between activated NK cells and improved survival in GBM patients was in contrast to increased CD39 and IL-10 in patients with a detrimental course and very short survival. Recursive partitioning analysis (RPA) and Cox proportional hazards models substantiated the relevance of absolute numbers of CD8 cells and low numbers of CD39 cells for better survival. CONCLUSIONS: Defined alterations of the immune system may guide the course of disease in patients with GBM and may be prognostically valuable for longitudinal studies or can be applied for immune intervention. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0272-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5009501
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50095012016-09-03 Immune phenotypes predict survival in patients with glioblastoma multiforme Mostafa, Haouraa Pala, Andrej Högel, Josef Hlavac, Michal Dietrich, Elvira Westhoff, M. Andrew Nonnenmacher, Lisa Burster, Timo Georgieff, Michael Wirtz, C. Rainer Schneider, E. Marion J Hematol Oncol Research BACKGROUND: Glioblastoma multiforme (GBM), a common primary malignant brain tumor, rarely disseminates beyond the central nervous system and has a very bad prognosis. The current study aimed at the analysis of immunological control in individual patients with GBM. METHODS: Immune phenotypes and plasma biomarkers of GBM patients were determined at the time of diagnosis using flow cytometry and ELISA, respectively. RESULTS: Using descriptive statistics, we found that immune anomalies were distinct in individual patients. Defined marker profiles proved highly relevant for survival. A remarkable relation between activated NK cells and improved survival in GBM patients was in contrast to increased CD39 and IL-10 in patients with a detrimental course and very short survival. Recursive partitioning analysis (RPA) and Cox proportional hazards models substantiated the relevance of absolute numbers of CD8 cells and low numbers of CD39 cells for better survival. CONCLUSIONS: Defined alterations of the immune system may guide the course of disease in patients with GBM and may be prognostically valuable for longitudinal studies or can be applied for immune intervention. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0272-3) contains supplementary material, which is available to authorized users. BioMed Central 2016-09-01 /pmc/articles/PMC5009501/ /pubmed/27585656 http://dx.doi.org/10.1186/s13045-016-0272-3 Text en © Mostafa et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Mostafa, Haouraa
Pala, Andrej
Högel, Josef
Hlavac, Michal
Dietrich, Elvira
Westhoff, M. Andrew
Nonnenmacher, Lisa
Burster, Timo
Georgieff, Michael
Wirtz, C. Rainer
Schneider, E. Marion
Immune phenotypes predict survival in patients with glioblastoma multiforme
title Immune phenotypes predict survival in patients with glioblastoma multiforme
title_full Immune phenotypes predict survival in patients with glioblastoma multiforme
title_fullStr Immune phenotypes predict survival in patients with glioblastoma multiforme
title_full_unstemmed Immune phenotypes predict survival in patients with glioblastoma multiforme
title_short Immune phenotypes predict survival in patients with glioblastoma multiforme
title_sort immune phenotypes predict survival in patients with glioblastoma multiforme
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009501/
https://www.ncbi.nlm.nih.gov/pubmed/27585656
http://dx.doi.org/10.1186/s13045-016-0272-3
work_keys_str_mv AT mostafahaouraa immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme
AT palaandrej immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme
AT hogeljosef immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme
AT hlavacmichal immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme
AT dietrichelvira immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme
AT westhoffmandrew immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme
AT nonnenmacherlisa immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme
AT burstertimo immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme
AT georgieffmichael immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme
AT wirtzcrainer immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme
AT schneideremarion immunephenotypespredictsurvivalinpatientswithglioblastomamultiforme